Display options
Cite
Liu W, Wang S, Qian K, et al. Expression of family with sequence similarity 172 member A and nucleotide-binding protein 1 is associated with the poor prognosis of colorectal carcinoma. Oncol Lett. 2017;14(3):3587-3593doi: 10.3892/ol.2017.6585.
Liu, W., Wang, S., Qian, K., Zhang, J., Zhang, Z., & Liu, H. (2017). Expression of family with sequence similarity 172 member A and nucleotide-binding protein 1 is associated with the poor prognosis of colorectal carcinoma. Oncology letters, 14(3), 3587-3593. https://doi.org/10.3892/ol.2017.6585
Liu, Wenjun, et al. "Expression of family with sequence similarity 172 member A and nucleotide-binding protein 1 is associated with the poor prognosis of colorectal carcinoma." Oncology letters vol. 14,3 (2017): 3587-3593. doi: https://doi.org/10.3892/ol.2017.6585
Liu W, Wang S, Qian K, Zhang J, Zhang Z, Liu H. Expression of family with sequence similarity 172 member A and nucleotide-binding protein 1 is associated with the poor prognosis of colorectal carcinoma. Oncol Lett. 2017 Sep;14(3):3587-3593. doi: 10.3892/ol.2017.6585. Epub 2017 Jul 15. PMID: 28927116; PMCID: PMC5588006.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Sep;14(3):3587-3593. doi: 10.3892/ol.2017.6585. Epub 2017 Jul 15.

Expression of family with sequence similarity 172 member A and nucleotide-binding protein 1 is associated with the poor prognosis of colorectal carcinoma.

Oncology letters

Wenjun Liu, Shuang Wang, Kai Qian, Jinqian Zhang, Zhi Zhang, Hao Liu

Affiliations

  1. Department of Vascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
  2. Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
  3. Department of Laboratory Medicine, The Second People's Hospital of Guangdong, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.

PMID: 28927116 PMCID: PMC5588006 DOI: 10.3892/ol.2017.6585

Abstract

In our previous studies, a functionally unknown gene, family with sequence similarity 172, member A (FAM172A), was identified. High levels of FAM172A suppressed the cell cycle process, arresting HepG2 cells in G1/S and inhibiting cell proliferation. The present study aimed to confirm the expression levels of FAM172A and nucleotide-binding protein 1 (NUBP1) in colorectal cancer (CRC) tissues and normal colorectal tissues. The impact of FAM172A and NUBP1 on the prognosis of patients with CRC was also analyzed. Immunohistochemical staining for FAM172A and NUBP1 was performed on 180 cancerous tissues and 60 normal paraffin-embedded tissues from patients with CRC. In total, 85 and 83% of 180 patients revealed positive expression of FAM172A and NUBP1, respectively. FAM172A expression level was associated with Tumor-Node-Metastasis (TNM) staging (P<0.001), the levels of serum carcinoembryonic antigen (CEA; P=0.023) and carbohydrate antigen 19-9 (CA19-9; P=0.016), lymph node involvement (P=0.004), tissue type (P=0.016), Dukes' staging (P<0.001) and NUBP1 (P=0.026). Furthermore, the expression level of NUBP1 was also markedly associated with the levels of serum CEA (P=0.006) and CA19-9 (P=0.001), TNM staging (P<0.001), lymph node involvement (P=0.005), histological typing (P=0.024) and Dukes' stage (P<0.001). Results of the univariate analysis demonstrated that there was a negative correlation between the expression level of FAM172A and overall survival (OS) and relapse-free survival (RFS) (P=0.013 and P=0.012, respectively), and there was also a negative correlation between NUBP1 expression level and OS and RFS (P<0.001 and P<0.001, respectively). With regards to OS and RFS, multivariate analysis revealed that expression levels of FAM172A and NUBP1 and tumor stage may be independent prognostic factors Thus, the present study suggested that FAM172A and NUBP1 may be prognostic makers for CRC.

Keywords: colorectal carcinoma; expression; family with sequence similarity 172; member A; nucleotide-binding protein 1; poor prognosis

References

  1. Proteins. 2006 Aug 15;64(3):643-51 - PubMed
  2. Lancet. 2014 Apr 26;383(9927):1490-1502 - PubMed
  3. Semin Cancer Biol. 2002 Apr;12(2):89-96 - PubMed
  4. EMBO J. 2011 Jul 22;30(16):3337-52 - PubMed
  5. Cell Mol Life Sci. 2016 Jan;73(1):163-84 - PubMed
  6. Zhonghua Yi Xue Za Zhi. 2009 Sep 29;89(36):2574-7 - PubMed
  7. Gene. 2000 Apr 4;246(1-2):395-404 - PubMed
  8. Mol Biol Cell. 2006 Apr;17(4):1959-70 - PubMed
  9. Oncol Rep. 2013 Mar;29(3):1154-60 - PubMed
  10. Mol Biol Rep. 2010 Mar;37(3):1165-8 - PubMed
  11. J Cell Sci. 2006 May 15;119(Pt 10):2035-47 - PubMed
  12. Dig Liver Dis. 2012 Mar;44(3):195-200 - PubMed
  13. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  14. BMC Cancer. 2013 Jul 31;13:366 - PubMed
  15. Ann Surg Oncol. 2010 Jun;17(6):1471-4 - PubMed
  16. Mol Cell Biol. 2008 Sep;28(17):5517-28 - PubMed
  17. Anticancer Res. 2014 Aug;34(8):4239-45 - PubMed
  18. Cell Mol Life Sci. 2014 Feb;71(3):517-38 - PubMed
  19. Genomics. 1999 Sep 1;60(2):152-60 - PubMed
  20. Nat Rev Cancer. 2003 Jan;3(1):55-63 - PubMed

Publication Types